autoimmune disease

Three blocks displaying from left to right a person a handshake and another person
Biotech

Boehringer makes €407M bet on Immunitas’ inflammatory asset

Boehringer secured global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory and autoimmune diseases.
Nick Paul Taylor May 12, 2026 9:57am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

UCB inks $2B Candid buyout to join Gilead in autoimmune field

May 4, 2026 7:46am
Golfer devastated after just barely missing a putt

Amgen abandons cancer, Sjögren’s drugs over weak ph.2 data

May 1, 2026 1:45am
Uninhabited island full of trees

Rebranded biotech lands $125M for rescued Galapagos assets

Apr 28, 2026 7:00am
Assorted cleaning supplies sitting on a wooden table

Astellas thins early pipeline, swaps out struggling gene therapy

Apr 27, 2026 10:38am
Close-up of shredded document

Lilly reneges on remainder of Rigel RIPK1 deal

Apr 22, 2026 3:00pm